Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies ; day:30 ; month:8 ; year:2016 ; pages:1-12
Dermatology and therapy ; (30.8.2016), 1-12
- Creator
-
Kircik, Leon
- Contributor
-
Fowler, Joseph
Weiss, Jonathan
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
SpringerLink (Online service)
- DOI
-
10.1007/s13555-016-0139-0
- URN
-
urn:nbn:de:1111-201609272825
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kircik, Leon
- Fowler, Joseph
- Weiss, Jonathan
- Meng, Xiangyi
- Guana, Adriana
- Nyirady, Judit
- SpringerLink (Online service)
Other Objects (12)
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
Secukinumab (Psoriasis-Arthritis) : Addendum zum Auftrag A20-80
Secukinumab wirksam bei axialen Manifestationen der Psoriasis-Arthritis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
Secukinumab (Psoriasis-Arthritis) : Addendum zum Auftrag A20-80
Secukinumab wirksam bei axialen Manifestationen der Psoriasis-Arthritis
Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
Secukinumab (Psoriasis-Arthritis) : Addendum zum Auftrag A20-80
Secukinumab wirksam bei axialen Manifestationen der Psoriasis-Arthritis